Skip to main content
. 2015 Oct 14;154(1):171–180. doi: 10.1007/s10549-015-3597-7

Fig. 1.

Fig. 1

Kaplan–Meier estimates of the contralateral breast cancer (CBC) risk in BRCA1/2 mutation carriers, younger than 40 years of age at primary BC diagnosis. For this analysis, left truncation of analysis time at the DNA test date was applied, to correct for survival bias. Patients treated with radiotherapy (either after lumpectomy or after mastectomy) were compared to those not treated with radiotherapy at primary BC diagnosis